Dr Reddy's lines up Rs 1,000 cr capex for FY22Illustrative image – not actual.
Drug major Dr Reddy's Laboratories has earmarked a capex of around Rs 1,000 crore for FY22 as it remains positive about sustaining its growth trends in FY22 and beyond.

The Hyderabad-based firm invested about Rs 1,000 crore in FY21. The drug maker's growth will be primarily driven by organic moves, focusing around pipeline monetisation, productivity enhancement, diversifications and capability ramp-up in marketing and digitalization.

As of 31 March 2021, the drug maker had 95 cumulative filings pending approval with the US Food and Drug Administration (USFDA), which included 92 abbreviated new drug applications (ANDAs) and three new drug applications (NDAs).

← All latest storiesBack to top →